天辰生物医药再度递表港交所
Zhi Tong Cai Jing·2026-02-25 22:35
Group 1 - Tianchen Biopharma (Suzhou) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Guotai Junan Securities (Hong Kong) as the sole sponsor [1] - The company focuses on the discovery and development of biopharmaceuticals targeting allergic and autoimmune diseases, currently in the clinical stage [1] - The core product, LP-003, is an anti-IgE antibody designed to block free IgE in blood and tissues, aiming to treat allergic diseases such as allergic rhinitis, chronic spontaneous urticaria, and allergic asthma [1]